We talk a lot about the treatment of relapsing-remitting MSM but we really want to develop more treatment options for progressive MS.
Dirucotide (MBP8298) is being studied in clinical trials for the treatment of secondary progressive MS (SPMS) at 68 sites with approximately 510 patients. The FDA has given fast track status because of the... Read more
We are getting closer the release of the first oral
medicines in the treatment of Relapsing-Remitting MS (RRMS) with the goal of
preventing relapses (and hopefully progression and disability). Altruistic patients
worldwide are taking part in multiple clinical trials testing the safety and
efficacy (effectiveness) of these new forms of... Read more
Our thoughts are with the patients and families in Europe
who recently developed PML (Progressive Multifocal Leukoencephalopathy) on
Natalizumab (Tysabri®).
When Tysabri® was being developed a few years ago, there was
a lot of hope in the MS Community about the idea of a non injectable disease
modifying agent for the... Read more
Multiple Sclerosis (MS) is thought of as an autoimmune disease affecting the Central Nervous System. But what does that mean? Autoimmune means that the body's defense (immune) system is confused and attacks the body itself instead of foreign invaders (such as viruses). But usually in MS the part of the body that is attacked is the Central... Read more
Multiple Sclerosis care is so rewarding because it is so multi-faceted - from the different types of presentation, different patients, different personalities, and different medication options. Fifteen years ago there were no FDA approved medications for MS. That has changed rapidly and so the pipeline for new medications grows every year... Read more